BIOLOGIAL RESPONSE MODIFIERS AS THERAPIES FOR AIDS

本合同的目的是为进入 生物反应调节剂(BRM)进入临床试验。这将是 通过检查BRMS的潜在功效来实现 一种合适的逆转录病毒感染动物模型。我们将努力 用于单独或与其他药物联合评估BRM 在适当的动物/逆转录病毒模型中确定它们的 作为一种治疗艾滋病的潜在有用方法。BRM是代理或 用于改变宿主对感染的生物反应的方法 从而产生治疗效果。BRMS可能在以下方面发挥作用 有好几种方法。有些通过以下方式增强宿主的抗病毒反应 直接或间接地增加或恢复效应器手臂。 其他的可能起到促进生长和分化的作用 淋巴细胞或巨噬细胞因此增加了 宿主耐受可能在体内使用的细胞毒性药物的损害 艾滋病的治疗。细胞因子，淋巴因子，单因子， 生长因子、肿瘤坏死因子及其诱导物 蛋白质是迄今为止已知的一些BRM的例子。这个 美国国家癌症学会肿瘤治疗分会 该研究所正在开发这些药物来治疗 肿瘤。直到最近，还没有做什么工作来开发 BRMS单独使用或与其他药物联合使用治疗 病毒感染的治疗。可能是艾滋病的治疗方法 需要长期使用抗病毒药物进行治疗(例如 核苷类似物)可能需要与 免疫反应的分子。BRMS可以用来 通过增加药物的数量来降低药物的毒性 淋巴细胞或辅助免疫反应来对抗这种病毒 感染。目前，对这一领域的研究需要 增加了。本次征集的目的是开发使用 用于艾滋病治疗的BRM。这将通过以下方式实现 评价BRMS单独或与其他药物联合应用 模拟艾滋病疾病的逆转录病毒动物模型。

The objective of this contract is to facilitate the entry of biological response modifiers (BRMs) into clinical trials. This will be accomplished by examining the potential efficacy of BRMs in an appropriate retrovirus infected animal model. Efforts will be made to evaluate BRMs alone or in combination with other drugs in an appropriate animal/retrovirus model to determine their potential usefulness as a therapy for AIDS. BRMs are agents or methods used to alter the host's biological response to infection with a resultant therapeutic effect. BRMs may function in several ways. Some increase the host's antiviral responses by augmenting or restoring the effector arms directly or indirectly. Others may function to increase the growth and differentiation of lymphocytes or macrophages thus increasing the ability of the host to tolerate damage by cytotoxic drugs that may be used in the treatment of AIDS. Cytokines, lymphokines, monokines, growth factors, tumor necrosis factors and inducers of these proteins are examples of some of the BRMs known to date. The Division of Cancer Treatment (DCT) of the National Cancer Institute has ben developing these agents in the treatment of tumors. Until recently little work has been done to develop the use of BRMs alone or in combination with other drugs for the treatment of viral infections. It may be that therapies for AIDS which require long term treatment with an antiviral agent (e.g. nucleoside analogue) may require combination therapy with a modualtor of the immune response. BRMs could be used to decrease the toxicity of the drug by increasing the number of lymphocytes or aid in the immune response against this viral infection. At present, research into this area needs to be increased. It is the purpose of this solicitation to develop the use of BRMs for AIDS therapy. This will be accomplished by evaluation BRMs alone or in combination with other drugs in an retrovirusanimal model which mimics the disease AIDS.